BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home
»
Newsletters
» BioWorld
BioWorld
June 6, 2006
View Archived Issues
Tysabri Cleared; FDA Gives 'Very Rare' Second Approval
The FDA is allowing Tysabri to return to the market in a limited capacity for multiple sclerosis patients, three months after an advisory committee voted unanimously in favor of doing so. (BioWorld Today)
Read More
Genelabs' HCV Program Nets Potential $200M Novartis Deal
Read More
Early ASCO Headlines Made By Pharma's Sutent, Tykerb
Read More
Cervarix Showing Promise As Cervical Cancer Field Crowds
Read More
Myogen Starting Phase III For BP-Lowering Drug Darusentan
Read More
Other News To Note
Read More
